Current Strategies for Vaccine Prophylaxis of Lyme Disease
Relevance. Lyme disease (LD) remains an important public health problem, especially in Russia, where the incidence is consistently high. To date, there is still no available vaccine against LD, and prevention involves non-specific measures. Aim: to review the literature and summarise data on progres...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Numikom LLC
2024-05-01
|
| Series: | Эпидемиология и вакцинопрофилактика |
| Subjects: | |
| Online Access: | https://www.epidemvac.ru/jour/article/view/1974 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250380596117504 |
|---|---|
| author | N. M. Kolyasnikova E. A. Artamonova A. A. Erovichenkov S. K. Pylaeva A. V. Belyakova A. A. Ishmukhametov |
| author_facet | N. M. Kolyasnikova E. A. Artamonova A. A. Erovichenkov S. K. Pylaeva A. V. Belyakova A. A. Ishmukhametov |
| author_sort | N. M. Kolyasnikova |
| collection | DOAJ |
| description | Relevance. Lyme disease (LD) remains an important public health problem, especially in Russia, where the incidence is consistently high. To date, there is still no available vaccine against LD, and prevention involves non-specific measures. Aim: to review the literature and summarise data on progress, approaches and strategies for LD vaccine development. Conclusions. The first LD vaccines were developed in the 1990s. An OspA-based vaccine (LYMErix) was commercially available in the early 2000s but not widely distributed. An important milestone in the development of LD vaccines was the shift from the development of monovalent vaccines based on a single type of outer surface protein to the development of multivalent combinations that provide protection against different Borrelia genospecies. A multivalent OspA-based vaccine (VLA15) is in phase III clinical trials and is likely to be the next LD vaccine available on the market. New genetic strategies for vaccine development, identification of new immunogens, and development of vaccines targeting different parts of the LD transmission cycle are of broad interest for further development of LD vaccines. |
| format | Article |
| id | doaj-art-82af8d5014d34e15a2a536ecce8fc4c1 |
| institution | Kabale University |
| issn | 2073-3046 2619-0494 |
| language | Russian |
| publishDate | 2024-05-01 |
| publisher | Numikom LLC |
| record_format | Article |
| series | Эпидемиология и вакцинопрофилактика |
| spelling | doaj-art-82af8d5014d34e15a2a536ecce8fc4c12025-08-20T03:57:17ZrusNumikom LLCЭпидемиология и вакцинопрофилактика2073-30462619-04942024-05-0123210211310.31631/2073-3046-2024-23-2-102-1131025Current Strategies for Vaccine Prophylaxis of Lyme DiseaseN. M. Kolyasnikova0E. A. Artamonova1A. A. Erovichenkov2S. K. Pylaeva3A. V. Belyakova4A. A. Ishmukhametov5M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the RAS (Polio Institute); Central Research Institute of Epidemiology of RospotrebnadzorM.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the RAS (Polio Institute)M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the RAS (Polio Institute)M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the RAS (Polio Institute)M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the RAS (Polio Institute)M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the RAS (Polio Institute)Relevance. Lyme disease (LD) remains an important public health problem, especially in Russia, where the incidence is consistently high. To date, there is still no available vaccine against LD, and prevention involves non-specific measures. Aim: to review the literature and summarise data on progress, approaches and strategies for LD vaccine development. Conclusions. The first LD vaccines were developed in the 1990s. An OspA-based vaccine (LYMErix) was commercially available in the early 2000s but not widely distributed. An important milestone in the development of LD vaccines was the shift from the development of monovalent vaccines based on a single type of outer surface protein to the development of multivalent combinations that provide protection against different Borrelia genospecies. A multivalent OspA-based vaccine (VLA15) is in phase III clinical trials and is likely to be the next LD vaccine available on the market. New genetic strategies for vaccine development, identification of new immunogens, and development of vaccines targeting different parts of the LD transmission cycle are of broad interest for further development of LD vaccines.https://www.epidemvac.ru/jour/article/view/1974lyme diseasevaccination |
| spellingShingle | N. M. Kolyasnikova E. A. Artamonova A. A. Erovichenkov S. K. Pylaeva A. V. Belyakova A. A. Ishmukhametov Current Strategies for Vaccine Prophylaxis of Lyme Disease Эпидемиология и вакцинопрофилактика lyme disease vaccination |
| title | Current Strategies for Vaccine Prophylaxis of Lyme Disease |
| title_full | Current Strategies for Vaccine Prophylaxis of Lyme Disease |
| title_fullStr | Current Strategies for Vaccine Prophylaxis of Lyme Disease |
| title_full_unstemmed | Current Strategies for Vaccine Prophylaxis of Lyme Disease |
| title_short | Current Strategies for Vaccine Prophylaxis of Lyme Disease |
| title_sort | current strategies for vaccine prophylaxis of lyme disease |
| topic | lyme disease vaccination |
| url | https://www.epidemvac.ru/jour/article/view/1974 |
| work_keys_str_mv | AT nmkolyasnikova currentstrategiesforvaccineprophylaxisoflymedisease AT eaartamonova currentstrategiesforvaccineprophylaxisoflymedisease AT aaerovichenkov currentstrategiesforvaccineprophylaxisoflymedisease AT skpylaeva currentstrategiesforvaccineprophylaxisoflymedisease AT avbelyakova currentstrategiesforvaccineprophylaxisoflymedisease AT aaishmukhametov currentstrategiesforvaccineprophylaxisoflymedisease |